Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates. “Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients,” said , President, Chairman and CEO of Genelux. “Looking ahead, we are excited about advancing Olvi-Vec into additional cancer indica...
The Lovesac Company Reports Fourth Quarter and Fiscal 2024 Financial Results Fourth Quarter Net Sales Growth of 5.0%Fiscal Year Net Sales Growth of 7.5% STAMFORD, Conn., April 11, 2024 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the fourth quarter and fiscal 2024, which ended February 4, 2024. Note: Lovesac's fourth quarter and fiscal 2024 results contain an additional, non-comparable week, or the "5...
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update – Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 – – Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer expected interim readout in 2H 2024 – – $23.2 m...
The Lovesac Company to Announce Fourth Quarter and Fiscal 2024 Earnings Results STAMFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) today announced that its fourth quarter and fiscal 2024 financial results will be released before market open on Thursday, April 11, 2024. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (international callers please dial 201-493-6780) approximately 10 minutes prior to the start...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.